23 Scopus citations


The current era of effective antiretroviral therapy has led to a marked reduction in opportunistic infections (OIs) in those countries where such therapies are available. Opportunistic fungal infections are no exception, and the incidence of such infections is now 20% to 25% of that seen in the mid-1990s. Infections associated with very advanced HIV disease, such as azole-resistant candidiasis and aspergillosis, are also rarely seen, reflecting the improvement in immune function. Indeed, the most common issue now is whether patients who have had a systemic mycosis require lifelong therapy as had been recommended. Preliminary data from small studies suggest that as with other OIs, it may be possible to stop suppressive therapy in patients with a history of mycosis whose CD4+ lymphocyte count rises with antiretroviral therapy. Thus, it appears that the future of HIV-associated mycoses is linked to the future of effective treatment for HIV itself.

Original languageEnglish
Pages (from-to)365-378
Number of pages14
JournalAIDS Reader
Issue number7
StatePublished - 2001


  • Azoles
  • Immune reconstitution
  • Mycoses
  • Opportunistic infections


Dive into the research topics of 'The changing face of mycoses in patients with HIV/AIDS'. Together they form a unique fingerprint.

Cite this